Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sprout Health vs CLYR Health

Two GLP-1 desks, one scoreboard. We put Sprout Health and CLYR Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 6 · Grade B

Sprout Health

Visit Sprout Health Full brief →
vs
No. 154 · Grade C

CLYR Health

Visit CLYR Health Full brief →

The verdict

Sprout Health takes this head-to-head.

Sprout Health scores 86 to 68 on our six-factor Brief Score — A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.

That doesn't make CLYR Health a bad call — it's best for readers who want flat-rate compounded glp-1 with pricing that does not increase as your dose goes up. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
46
Supply Reliability
82
84
Transparency
88
72
Access Breadth
92
62
Clinical Oversight
78
74
Track Record
84
80
Sprout HealthBrief Score 86 · 68CLYR Health

Price, coverage & the tracker

Sprout HealthCLYR Health
Brief Score86/100 (B)68/100 (C)
Semaglutide$149/moFrom $229/mo (compounded)
Tirzepatide$199/moFrom $249/mo (compounded)
CoverageNot disclosedCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

Sprout Health: Compounded $149 semaglutide / $199 tirzepatide held flat this cycle, with a brand-name Wegovy/Zepbound path available on the same account.

CLYR Health: New to the tracker on 1 August 2026. The published line reads From $229/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.